Skye Bioscience Inc. (SKYE) jumped 58.78 percent to $2.08 during Tuesday's trading after unveiling encouraging preclinical data for its novel CB1 antibody, nimacimab.
The stock opened at $1.48 and surged to a high of $3.73 before retreating on the Nasdaq. Volume reached 23 million shares, well above the average of 200,000. Skye has traded between $1.14 and $17.65 over the past year.
The company highlighted the treatment's potential to address obesity both as a standalone therapy and in combination with GLP-1 drugs. Skye anticipates initial results from its Phase 2a obesity study in late Q3 or early Q4 of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.